A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Dimier N, Delmar P, Ward C, Morariu-Zamfir R, Fingerle-Rowson G, Bahlo J, Fischer K, Eichhorst B, Goede V, van Dongen JJM, Ritgen M, Böttcher S, Langerak AW, Kneba M, Hallek M.
Dimier N, et al. Among authors: delmar p.
Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.
Blood. 2018.
PMID: 29255066
Free article.
Clinical Trial.